OTCMKTS:RLMD

Relmada Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy RLMD

*Your capital is at risk

$6.33

-0.0900 (-1.40%)

At Close: Jun 03, 2026

Relmada Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 13.96M and sold 702.47K RLMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	13.96M shares
● Sell	702.47K shares
84% Buy Activity Weak Positive Correlation
Buy Signal High Confidence Nov 05, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 15, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	27 500 Value: $113.3K
Dec 15, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	11 665 Value: $48.1K
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Casamento Charles J Director	Director	164 000 Value: $665.8K
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Kelly Paul Edward COO	C-Suite Officer	828 000 Value: $3.36M
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Glasspool John Director	Director	164 000 Value: $665.8K
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Traversa Sergio Chief Executive Officer	CEO / President	1 198 000 Value: $4.86M
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Shenouda Maged Chief Financial Officer	C-Suite Officer	828 000 Value: $3.36M
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Ence Chuck Ca And Co	Officer	828 000 Value: $3.36M
Dec 12, 2025 Buy	Stock Appreciation Rights A-Award	Fedeli Fabiana Director	Director	164 000 Value: $665.8K
Nov 05, 2025 Buy	Common Stock P-Purchase	Shenouda Maged Chief Financial Officer	C-Suite Officer	500 000 Value: $1.10M
Nov 05, 2025 Buy	Common Stock P-Purchase	Ence Chuck Cao And COO	C-Suite Officer	136 000 Value: $299.2K
Nov 05, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	272 500 Value: $599.5K
Nov 05, 2025 Buy	Common Stock P-Purchase	Kelly Paul Edward Chief Operating Officer	C-Suite Officer	90 000 Value: $198.0K
Aug 28, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	55 976 Value: $41.4K
Aug 28, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	55 976 Value: $41.4K
Aug 27, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	129 455 Value: $86.7K
Aug 27, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	129 455 Value: $86.7K
Aug 26, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	80 545 Value: $49.9K
Aug 26, 2025 Buy	Common Stock P-Purchase	Traversa Sergio Chief Executive Officer	CEO / President	80 545 Value: $49.9K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Ence Chuck Ca And Co	Officer	400 000 Value: $268.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Shenouda Maged Chief Financial Officer	C-Suite Officer	600 000 Value: $402.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Traversa Sergio Chief Executive Officer	CEO / President	800 000 Value: $536.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Casamento Charles J Director	Director	100 000 Value: $67.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Glasspool John Director	Director	100 000 Value: $67.0K
Jun 26, 2025 Buy	Stock Option (right to buy) A-Award	Fedeli Fabiana Director	Director	100 000 Value: $67.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RELMADA THERAPEUTICS, INC.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ...

Read Full Profile Here